Front Row Advisors’s Allogene Therapeutics ALLO Stock Holding History

Front Row Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$15K	–	928
2021 Q4	$15K	Buy	+1,000	New	+$17.6K	0.01%	475

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Front Row Advisors's ALLO Position: Q1 2022 in Review

Front Row Advisors sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 1,000 shares — an estimated $15K sold.

Front Row Advisors first reported a position in ALLO in Q4 2021 and held it in 1 quarter. The position peaked at $15K in Q4 2021. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

Front Row Advisors reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
Front Row Advisors sold 1,000 Allogene Therapeutics shares in Q1 2022, an estimated $15K.
Front Row Advisors first reported a position in Allogene Therapeutics in Q4 2021 and held it in 1 quarter.
Front Row Advisors's Allogene Therapeutics position peaked at $15K in Q4 2021.
180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Front Row Advisors's 13F filing for Q1 2022, filed 11 May 2022.